General information
    ACovPid:ACoVP100378
    Trivial Name:P1
    Amino Acids Sequence:GINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE
    Length:37
    C-Terminal Modification:None
    N-Terminal Modification:None
    Chemical Modification:None
    Peptide Source:

    Severe acute respiratory syndrome coronavirus (SARS-CoV) : 694009

    Source Description:From the heptad repeat region 2 of spike protein of SARS-CoV
    Against Virus:

    Severe acute respiratory syndrome coronavirus (SARS-CoV) : 694009

    Inhibition Value Type:IC50
    Inhibitory Effect:0.62 ± 0.20
    Inhibitory Unit:µM
    Target Domain Name:
    Assay:Cell–cell fusion assay
    Assay Description:The cell fusion inhibition assay is modified from a previously described β-galactosidase reporter gene-based SARS-CoV cell fusion assay (PMID: 14651994, 15492138). VRC(S)8304, a plasmid containing the S gene of SARS-CoV with humanized codon usage, is designated as S(h) in this study (PMID: 15492138). To construct pCDNA3HA-ACE2, total RNA extracted from VeroE6 cells by the Qiagen RNeasy mini kit (Qiagen, Valencia, CA) was subjected to RT using random primers, followed by PCR using the primer pair (NotI-ACE2, 5′-AAGGAAAAAAGCGGCCGCCGATGTCAAGCTCTTCC-3′ and XhoI-ACE2, 5′-CCCGCTC GAGCTAAAAGGAGGTCTGAAC-3′), digestion of the product with NotI and XhoI, and cloning into respective sites of pCDNA3-HA (Invitrogen, Carlsbad, CA). The construct was confirmed by sequencing both junctions of the insert with T7 and SP6 primers. HeLa cells (1 × 10^6) transfected with 2 µg of S(h) (cells #1) by use of lipofectamine 2000 (Invitrogen, Carsblad, CA) were infected with recombinant vaccinia virus expressing β-galactosidase (vCB21R) at a multiplicity of infection (MOI) of 1 at 6 h post-transfection. HeLa cells (1 × 10^6) transfected with 2 µg of pCDNA3HA-ACE2 (cells #2) were infected with recombinant vaccinia virus expressing T7 polymerase (vTF7.3) at a MOI of 1. After adsorption at 37 °C for 2 h and replacement with fresh medium, both cells were incubated at 28 °C overnight, washed with 1× PBS once, trypsinized, washed with 1× PBS twice, and resuspended in DMEM containing 10% FCS. Both cells #1 and #2 (1 × 10^5 cells, each well) were added into 96-well in duplicates, pre-incubated with or without different concentrations of peptides (50 µl per well) at 37 °C for 20 min, and co-cultured at 37 °C for 3 h. Cell lysates were measured for β-galactosidase activity using the Galcto-Start kit (Applied Biosystems, Bedford, MA). The percentage of fusion is the ratio of β-galactosidase activity in the presence of peptide to that in the absence of peptide.
    Anti-CoV activity in vivo:
    Reference:18983873
    Comment:
    3D structure:

    StructureACoVP100378

    Structure Experiment Verified:NO
    Similar Peptides:ACoVP100242   ACoVP100121   ACoVP100122   ACoVP100118   ACoVP100124